Table of Content

1. Executive Summary
 1.1. Global Market Outlook
 1.2. Demand-side Trends
 1.3. Supply-side Trends
 1.4. Technology Roadmap Analysis
 1.5. Analysis and Recommendations
2. Market Overview
 2.1. Market Coverage / Taxonomy
 2.2. Market Definition / Scope / Limitations
3. Market Background
 3.1. Market Dynamics
  3.1.1. Drivers
  3.1.2. Restraints
  3.1.3. Opportunity
  3.1.4. Trends
 3.2. Scenario Forecast
  3.2.1. Demand in Optimistic Scenario
  3.2.2. Demand in Likely Scenario
  3.2.3. Demand in Conservative Scenario
 3.3. Opportunity Map Analysis
 3.4. Investment Feasibility Matrix
 3.5. PESTLE and Porter’s Analysis
 3.6. Regulatory Landscape
  3.6.1. By Key Regions
  3.6.2. By Key Countries
 3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019-2023 and Forecast, 2024-2034
 4.1. Historical Market Size Value (US$ Million) Analysis, 2019-2023
 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024-2034
  4.2.1. Y-o-Y Growth Trend Analysis
  4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Drug Class
 5.1. Introduction / Key Findings
 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2019-2023
 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2024-2034
  5.3.1. Corticosteroids
  5.3.2. Anti-fibrotic Drugs
  5.3.3. Immunotherapy
  5.3.4. Immunoglobulins
 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2019-2023
 5.5. Absolute $ Opportunity Analysis By Drug Class, 2024-2034
6. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Route of Administration
 6.1. Introduction / Key Findings
 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2019-2023
 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2024-2034
  6.3.1. Oral
  6.3.2. Injectable
  6.3.3. Topical
 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2019-2023
 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2024-2034
7. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Indication
 7.1. Introduction / Key Findings
 7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2019-2023
 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2024-2034
  7.3.1. Keloid
  7.3.2. Scleroderma
  7.3.3. Radiation-induced Skin Fibrosis
  7.3.4. Chronic Graft-Versus-Host Disease (GvHD)-Associated Cutaneous Fibrosis
 7.4. Y-o-Y Growth Trend Analysis By Indication , 2019-2023
 7.5. Absolute $ Opportunity Analysis By Indication , 2024-2034
8. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Distribution Channel
 8.1. Introduction / Key Findings
 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019-2023
 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024-2034
  8.3.1. Hospital Pharmacies
  8.3.2. Retail Pharmacies
  8.3.3. Drug Stores
  8.3.4. Online Pharmacies
 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019-2023
 8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024-2034
9. Global Market Analysis 2019-2023 and Forecast 2024-2034, By Region
 9.1. Introduction
 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019-2023
 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024-2034
  9.3.1. North America
  9.3.2. Latin America
  9.3.3. Western Europe
  9.3.4. Eastern Europe
  9.3.5. South Asia and Pacific
  9.3.6. East Asia
  9.3.7. Middle East and Africa
 9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  10.2.1. By Country
   10.2.1.1. U.S.
   10.2.1.2. Canada
  10.2.2. By Drug Class
  10.2.3. By Route of Administration
  10.2.4. By Indication
  10.2.5. By Distribution Channel
 10.3. Market Attractiveness Analysis
  10.3.1. By Country
  10.3.2. By Drug Class
  10.3.3. By Route of Administration
  10.3.4. By Indication
  10.3.5. By Distribution Channel
 10.4. Key Takeaways
11. Latin America Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  11.2.1. By Country
   11.2.1.1. Brazil
   11.2.1.2. Mexico
   11.2.1.3. Rest of Latin America
  11.2.2. By Drug Class
  11.2.3. By Route of Administration
  11.2.4. By Indication
  11.2.5. By Distribution Channel
 11.3. Market Attractiveness Analysis
  11.3.1. By Country
  11.3.2. By Drug Class
  11.3.3. By Route of Administration
  11.3.4. By Indication
  11.3.5. By Distribution Channel
 11.4. Key Takeaways
12. Western Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  12.2.1. By Country
   12.2.1.1. Germany
   12.2.1.2. U.K.
   12.2.1.3. France
   12.2.1.4. Spain
   12.2.1.5. Italy
   12.2.1.6. Rest of Western Europe
  12.2.2. By Drug Class
  12.2.3. By Route of Administration
  12.2.4. By Indication
  12.2.5. By Distribution Channel
 12.3. Market Attractiveness Analysis
  12.3.1. By Country
  12.3.2. By Drug Class
  12.3.3. By Route of Administration
  12.3.4. By Indication
  12.3.5. By Distribution Channel
 12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  13.2.1. By Country
   13.2.1.1. Poland
   13.2.1.2. Russia
   13.2.1.3. Czech Republic
   13.2.1.4. Romania
   13.2.1.5. Rest of Eastern Europe
  13.2.2. By Drug Class
  13.2.3. By Route of Administration
  13.2.4. By Indication
  13.2.5. By Distribution Channel
 13.3. Market Attractiveness Analysis
  13.3.1. By Country
  13.3.2. By Drug Class
  13.3.3. By Route of Administration
  13.3.4. By Indication
  13.3.5. By Distribution Channel
 13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  14.2.1. By Country
   14.2.1.1. India
   14.2.1.2. Bangladesh
   14.2.1.3. Australia
   14.2.1.4. New Zealand
   14.2.1.5. Rest of South Asia and Pacific
  14.2.2. By Drug Class
  14.2.3. By Route of Administration
  14.2.4. By Indication
  14.2.5. By Distribution Channel
 14.3. Market Attractiveness Analysis
  14.3.1. By Country
  14.3.2. By Drug Class
  14.3.3. By Route of Administration
  14.3.4. By Indication
  14.3.5. By Distribution Channel
 14.4. Key Takeaways
15. East Asia Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  15.2.1. By Country
   15.2.1.1. China
   15.2.1.2. Japan
   15.2.1.3. South Korea
  15.2.2. By Drug Class
  15.2.3. By Route of Administration
  15.2.4. By Indication
  15.2.5. By Distribution Channel
 15.3. Market Attractiveness Analysis
  15.3.1. By Country
  15.3.2. By Drug Class
  15.3.3. By Route of Administration
  15.3.4. By Indication
  15.3.5. By Distribution Channel
 15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019-2023 and Forecast 2024-2034, By Country
 16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019-2023
 16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024-2034
  16.2.1. By Country
   16.2.1.1. GCC Countries
   16.2.1.2. South Africa
   16.2.1.3. Israel
   16.2.1.4. Rest of MEA
  16.2.2. By Drug Class
  16.2.3. By Route of Administration
  16.2.4. By Indication
  16.2.5. By Distribution Channel
 16.3. Market Attractiveness Analysis
  16.3.1. By Country
  16.3.2. By Drug Class
  16.3.3. By Route of Administration
  16.3.4. By Indication
  16.3.5. By Distribution Channel
 16.4. Key Takeaways
17. Key Countries Market Analysis
 17.1. U.S.
  17.1.1. Pricing Analysis
  17.1.2. Market Share Analysis, 2023
   17.1.2.1. By Drug Class
   17.1.2.2. By Route of Administration
   17.1.2.3. By Indication
   17.1.2.4. By Distribution Channel
 17.2. Canada
  17.2.1. Pricing Analysis
  17.2.2. Market Share Analysis, 2023
   17.2.2.1. By Drug Class
   17.2.2.2. By Route of Administration
   17.2.2.3. By Indication
   17.2.2.4. By Distribution Channel
 17.3. Brazil
  17.3.1. Pricing Analysis
  17.3.2. Market Share Analysis, 2023
   17.3.2.1. By Drug Class
   17.3.2.2. By Route of Administration
   17.3.2.3. By Indication
   17.3.2.4. By Distribution Channel
 17.4. Mexico
  17.4.1. Pricing Analysis
  17.4.2. Market Share Analysis, 2023
   17.4.2.1. By Drug Class
   17.4.2.2. By Route of Administration
   17.4.2.3. By Indication
   17.4.2.4. By Distribution Channel
 17.5. Germany
  17.5.1. Pricing Analysis
  17.5.2. Market Share Analysis, 2023
   17.5.2.1. By Drug Class
   17.5.2.2. By Route of Administration
   17.5.2.3. By Indication
   17.5.2.4. By Distribution Channel
 17.6. U.K.
  17.6.1. Pricing Analysis
  17.6.2. Market Share Analysis, 2023
   17.6.2.1. By Drug Class
   17.6.2.2. By Route of Administration
   17.6.2.3. By Indication
   17.6.2.4. By Distribution Channel
 17.7. France
  17.7.1. Pricing Analysis
  17.7.2. Market Share Analysis, 2023
   17.7.2.1. By Drug Class
   17.7.2.2. By Route of Administration
   17.7.2.3. By Indication
   17.7.2.4. By Distribution Channel
 17.8. Spain
  17.8.1. Pricing Analysis
  17.8.2. Market Share Analysis, 2023
   17.8.2.1. By Drug Class
   17.8.2.2. By Route of Administration
   17.8.2.3. By Indication
   17.8.2.4. By Distribution Channel
 17.9. Italy
  17.9.1. Pricing Analysis
  17.9.2. Market Share Analysis, 2023
   17.9.2.1. By Drug Class
   17.9.2.2. By Route of Administration
   17.9.2.3. By Indication
   17.9.2.4. By Distribution Channel
 17.10. Poland
  17.10.1. Pricing Analysis
  17.10.2. Market Share Analysis, 2023
   17.10.2.1. By Drug Class
   17.10.2.2. By Route of Administration
   17.10.2.3. By Indication
   17.10.2.4. By Distribution Channel
 17.11. Russia
  17.11.1. Pricing Analysis
  17.11.2. Market Share Analysis, 2023
   17.11.2.1. By Drug Class
   17.11.2.2. By Route of Administration
   17.11.2.3. By Indication
   17.11.2.4. By Distribution Channel
 17.12. Czech Republic
  17.12.1. Pricing Analysis
  17.12.2. Market Share Analysis, 2023
   17.12.2.1. By Drug Class
   17.12.2.2. By Route of Administration
   17.12.2.3. By Indication
   17.12.2.4. By Distribution Channel
 17.13. Romania
  17.13.1. Pricing Analysis
  17.13.2. Market Share Analysis, 2023
   17.13.2.1. By Drug Class
   17.13.2.2. By Route of Administration
   17.13.2.3. By Indication
   17.13.2.4. By Distribution Channel
 17.14. India
  17.14.1. Pricing Analysis
  17.14.2. Market Share Analysis, 2023
   17.14.2.1. By Drug Class
   17.14.2.2. By Route of Administration
   17.14.2.3. By Indication
   17.14.2.4. By Distribution Channel
 17.15. Bangladesh
  17.15.1. Pricing Analysis
  17.15.2. Market Share Analysis, 2023
   17.15.2.1. By Drug Class
   17.15.2.2. By Route of Administration
   17.15.2.3. By Indication
   17.15.2.4. By Distribution Channel
 17.16. Australia
  17.16.1. Pricing Analysis
  17.16.2. Market Share Analysis, 2023
   17.16.2.1. By Drug Class
   17.16.2.2. By Route of Administration
   17.16.2.3. By Indication
   17.16.2.4. By Distribution Channel
 17.17. New Zealand
  17.17.1. Pricing Analysis
  17.17.2. Market Share Analysis, 2023
   17.17.2.1. By Drug Class
   17.17.2.2. By Route of Administration
   17.17.2.3. By Indication
   17.17.2.4. By Distribution Channel
 17.18. China
  17.18.1. Pricing Analysis
  17.18.2. Market Share Analysis, 2023
   17.18.2.1. By Drug Class
   17.18.2.2. By Route of Administration
   17.18.2.3. By Indication
   17.18.2.4. By Distribution Channel
 17.19. Japan
  17.19.1. Pricing Analysis
  17.19.2. Market Share Analysis, 2023
   17.19.2.1. By Drug Class
   17.19.2.2. By Route of Administration
   17.19.2.3. By Indication
   17.19.2.4. By Distribution Channel
 17.20. South Korea
  17.20.1. Pricing Analysis
  17.20.2. Market Share Analysis, 2023
   17.20.2.1. By Drug Class
   17.20.2.2. By Route of Administration
   17.20.2.3. By Indication
   17.20.2.4. By Distribution Channel
 17.21. GCC Countries
  17.21.1. Pricing Analysis
  17.21.2. Market Share Analysis, 2023
   17.21.2.1. By Drug Class
   17.21.2.2. By Route of Administration
   17.21.2.3. By Indication
   17.21.2.4. By Distribution Channel
 17.22. South Africa
  17.22.1. Pricing Analysis
  17.22.2. Market Share Analysis, 2023
   17.22.2.1. By Drug Class
   17.22.2.2. By Route of Administration
   17.22.2.3. By Indication
   17.22.2.4. By Distribution Channel
 17.23. Israel
  17.23.1. Pricing Analysis
  17.23.2. Market Share Analysis, 2023
   17.23.2.1. By Drug Class
   17.23.2.2. By Route of Administration
   17.23.2.3. By Indication
   17.23.2.4. By Distribution Channel
18. Market Structure Analysis
 18.1. Competition Dashboard
 18.2. Competition Benchmarking
 18.3. Market Share Analysis of Top Players
  18.3.1. By Regional
  18.3.2. By Drug Class
  18.3.3. By Route of Administration
  18.3.4. By Indication
  18.3.5. By Distribution Channel
19. Competition Analysis
 19.1. Competition Deep Dive
  19.1.1. Novartis AG
   19.1.1.1. Overview
   19.1.1.2. Product Portfolio
   19.1.1.3. Profitability by Market Segments
   19.1.1.4. Sales Footprint
   19.1.1.5. Strategy Overview
    19.1.1.5.1. Marketing Strategy
  19.1.2. Pfizer
   19.1.2.1. Overview
   19.1.2.2. Product Portfolio
   19.1.2.3. Profitability by Market Segments
   19.1.2.4. Sales Footprint
   19.1.2.5. Strategy Overview
    19.1.2.5.1. Marketing Strategy
  19.1.3. Sanofi
   19.1.3.1. Overview
   19.1.3.2. Product Portfolio
   19.1.3.3. Profitability by Market Segments
   19.1.3.4. Sales Footprint
   19.1.3.5. Strategy Overview
    19.1.3.5.1. Marketing Strategy
  19.1.4. Johnson & Johnson Services
   19.1.4.1. Overview
   19.1.4.2. Product Portfolio
   19.1.4.3. Profitability by Market Segments
   19.1.4.4. Sales Footprint
   19.1.4.5. Strategy Overview
    19.1.4.5.1. Marketing Strategy
  19.1.5. Boehringer Ingelheim International GmbH
   19.1.5.1. Overview
   19.1.5.2. Product Portfolio
   19.1.5.3. Profitability by Market Segments
   19.1.5.4. Sales Footprint
   19.1.5.5. Strategy Overview
    19.1.5.5.1. Marketing Strategy
  19.1.6. Jubilant Cadista
   19.1.6.1. Overview
   19.1.6.2. Product Portfolio
   19.1.6.3. Profitability by Market Segments
   19.1.6.4. Sales Footprint
   19.1.6.5. Strategy Overview
    19.1.6.5.1. Marketing Strategy
  19.1.7. Horizon Pharma USA, Inc.
   19.1.7.1. Overview
   19.1.7.2. Product Portfolio
   19.1.7.3. Profitability by Market Segments
   19.1.7.4. Sales Footprint
   19.1.7.5. Strategy Overview
    19.1.7.5.1. Marketing Strategy
  19.1.8. Brotol-Myers Squibb Company
   19.1.8.1. Overview
   19.1.8.2. Product Portfolio
   19.1.8.3. Profitability by Market Segments
   19.1.8.4. Sales Footprint
   19.1.8.5. Strategy Overview
    19.1.8.5.1. Marketing Strategy
  19.1.9. Teva Pharmaceuticals
   19.1.9.1. Overview
   19.1.9.2. Product Portfolio
   19.1.9.3. Profitability by Market Segments
   19.1.9.4. Sales Footprint
   19.1.9.5. Strategy Overview
    19.1.9.5.1. Marketing Strategy
  19.1.10. Amgen
   19.1.10.1. Overview
   19.1.10.2. Product Portfolio
   19.1.10.3. Profitability by Market Segments
   19.1.10.4. Sales Footprint
   19.1.10.5. Strategy Overview
    19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology



List of Figures

Figure 1: Global Market Value (US$ Million) by Drug Class, 2024-2034

Figure 2: Global Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 3: Global Market Value (US$ Million) by Indication , 2024-2034

Figure 4: Global Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 5: Global Market Value (US$ Million) by Region, 2024-2034

Figure 6: Global Market Value (US$ Million) Analysis by Region, 2019-2034

Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2024-2034

Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2024-2034

Figure 9: Global Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 10: Global Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 11: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 12: Global Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 13: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 14: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 15: Global Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 16: Global Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 17: Global Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 21: Global Market Attractiveness by Drug Class, 2024-2034

Figure 22: Global Market Attractiveness by Route of Administration, 2024-2034

Figure 23: Global Market Attractiveness by Indication , 2024-2034

Figure 24: Global Market Attractiveness by Distribution Channel, 2024-2034

Figure 25: Global Market Attractiveness by Region, 2024-2034

Figure 26: North America Market Value (US$ Million) by Drug Class, 2024-2034

Figure 27: North America Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 28: North America Market Value (US$ Million) by Indication , 2024-2034

Figure 29: North America Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 30: North America Market Value (US$ Million) by Country, 2024-2034

Figure 31: North America Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 34: North America Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 35: North America Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 36: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 37: North America Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 38: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 39: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 40: North America Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 41: North America Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 42: North America Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 46: North America Market Attractiveness by Drug Class, 2024-2034

Figure 47: North America Market Attractiveness by Route of Administration, 2024-2034

Figure 48: North America Market Attractiveness by Indication , 2024-2034

Figure 49: North America Market Attractiveness by Distribution Channel, 2024-2034

Figure 50: North America Market Attractiveness by Country, 2024-2034

Figure 51: Latin America Market Value (US$ Million) by Drug Class, 2024-2034

Figure 52: Latin America Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 53: Latin America Market Value (US$ Million) by Indication , 2024-2034

Figure 54: Latin America Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 55: Latin America Market Value (US$ Million) by Country, 2024-2034

Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 59: Latin America Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 60: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 62: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 63: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 65: Latin America Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 66: Latin America Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 71: Latin America Market Attractiveness by Drug Class, 2024-2034

Figure 72: Latin America Market Attractiveness by Route of Administration, 2024-2034

Figure 73: Latin America Market Attractiveness by Indication , 2024-2034

Figure 74: Latin America Market Attractiveness by Distribution Channel, 2024-2034

Figure 75: Latin America Market Attractiveness by Country, 2024-2034

Figure 76: Western Europe Market Value (US$ Million) by Drug Class, 2024-2034

Figure 77: Western Europe Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 78: Western Europe Market Value (US$ Million) by Indication , 2024-2034

Figure 79: Western Europe Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 80: Western Europe Market Value (US$ Million) by Country, 2024-2034

Figure 81: Western Europe Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 82: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 83: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 84: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 85: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 86: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 87: Western Europe Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 88: Western Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 89: Western Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 90: Western Europe Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 91: Western Europe Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 92: Western Europe Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 93: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 94: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 95: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 96: Western Europe Market Attractiveness by Drug Class, 2024-2034

Figure 97: Western Europe Market Attractiveness by Route of Administration, 2024-2034

Figure 98: Western Europe Market Attractiveness by Indication , 2024-2034

Figure 99: Western Europe Market Attractiveness by Distribution Channel, 2024-2034

Figure 100: Western Europe Market Attractiveness by Country, 2024-2034

Figure 101: Eastern Europe Market Value (US$ Million) by Drug Class, 2024-2034

Figure 102: Eastern Europe Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 103: Eastern Europe Market Value (US$ Million) by Indication , 2024-2034

Figure 104: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 105: Eastern Europe Market Value (US$ Million) by Country, 2024-2034

Figure 106: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 107: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 108: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 109: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 110: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 111: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 112: Eastern Europe Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 113: Eastern Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 114: Eastern Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 115: Eastern Europe Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 116: Eastern Europe Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 117: Eastern Europe Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 118: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 119: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 120: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 121: Eastern Europe Market Attractiveness by Drug Class, 2024-2034

Figure 122: Eastern Europe Market Attractiveness by Route of Administration, 2024-2034

Figure 123: Eastern Europe Market Attractiveness by Indication , 2024-2034

Figure 124: Eastern Europe Market Attractiveness by Distribution Channel, 2024-2034

Figure 125: Eastern Europe Market Attractiveness by Country, 2024-2034

Figure 126: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2024-2034

Figure 127: South Asia and Pacific Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 128: South Asia and Pacific Market Value (US$ Million) by Indication , 2024-2034

Figure 129: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 130: South Asia and Pacific Market Value (US$ Million) by Country, 2024-2034

Figure 131: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 132: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 133: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 134: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 135: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 136: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 137: South Asia and Pacific Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 138: South Asia and Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 139: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 140: South Asia and Pacific Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 141: South Asia and Pacific Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 142: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 143: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 144: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 145: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 146: South Asia and Pacific Market Attractiveness by Drug Class, 2024-2034

Figure 147: South Asia and Pacific Market Attractiveness by Route of Administration, 2024-2034

Figure 148: South Asia and Pacific Market Attractiveness by Indication , 2024-2034

Figure 149: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024-2034

Figure 150: South Asia and Pacific Market Attractiveness by Country, 2024-2034

Figure 151: East Asia Market Value (US$ Million) by Drug Class, 2024-2034

Figure 152: East Asia Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 153: East Asia Market Value (US$ Million) by Indication , 2024-2034

Figure 154: East Asia Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 155: East Asia Market Value (US$ Million) by Country, 2024-2034

Figure 156: East Asia Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 157: East Asia Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 158: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 159: East Asia Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 160: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 161: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 162: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 163: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 164: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 165: East Asia Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 166: East Asia Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 167: East Asia Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 168: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 169: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 170: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 171: East Asia Market Attractiveness by Drug Class, 2024-2034

Figure 172: East Asia Market Attractiveness by Route of Administration, 2024-2034

Figure 173: East Asia Market Attractiveness by Indication , 2024-2034

Figure 174: East Asia Market Attractiveness by Distribution Channel, 2024-2034

Figure 175: East Asia Market Attractiveness by Country, 2024-2034

Figure 176: Middle East and Africa Market Value (US$ Million) by Drug Class, 2024-2034

Figure 177: Middle East and Africa Market Value (US$ Million) by Route of Administration, 2024-2034

Figure 178: Middle East and Africa Market Value (US$ Million) by Indication , 2024-2034

Figure 179: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024-2034

Figure 180: Middle East and Africa Market Value (US$ Million) by Country, 2024-2034

Figure 181: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019-2034

Figure 182: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024-2034

Figure 183: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024-2034

Figure 184: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2019-2034

Figure 185: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2024-2034

Figure 186: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2024-2034

Figure 187: Middle East and Africa Market Value (US$ Million) Analysis by Route of Administration, 2019-2034

Figure 188: Middle East and Africa Market Value Share (%) and BPS Analysis by Route of Administration, 2024-2034

Figure 189: Middle East and Africa Market Y-o-Y Growth (%) Projections by Route of Administration, 2024-2034

Figure 190: Middle East and Africa Market Value (US$ Million) Analysis by Indication , 2019-2034

Figure 191: Middle East and Africa Market Value Share (%) and BPS Analysis by Indication , 2024-2034

Figure 192: Middle East and Africa Market Y-o-Y Growth (%) Projections by Indication , 2024-2034

Figure 193: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019-2034

Figure 194: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024-2034

Figure 195: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024-2034

Figure 196: Middle East and Africa Market Attractiveness by Drug Class, 2024-2034

Figure 197: Middle East and Africa Market Attractiveness by Route of Administration, 2024-2034

Figure 198: Middle East and Africa Market Attractiveness by Indication , 2024-2034

Figure 199: Middle East and Africa Market Attractiveness by Distribution Channel, 2024-2034

Figure 200: Middle East and Africa Market Attractiveness by Country, 2024-2034

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2019-2034

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 4: Global Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 5: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 6: North America Market Value (US$ Million) Forecast by Country, 2019-2034

Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 8: North America Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 9: North America Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2019-2034

Table 12: Latin America Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 13: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 14: Latin America Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 16: Western Europe Market Value (US$ Million) Forecast by Country, 2019-2034

Table 17: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 18: Western Europe Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 19: Western Europe Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 20: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 21: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019-2034

Table 22: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 23: Eastern Europe Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 24: Eastern Europe Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 25: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 26: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019-2034

Table 27: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 28: South Asia and Pacific Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 29: South Asia and Pacific Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 30: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 31: East Asia Market Value (US$ Million) Forecast by Country, 2019-2034

Table 32: East Asia Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 33: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 34: East Asia Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 35: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034

Table 36: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019-2034

Table 37: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2019-2034

Table 38: Middle East and Africa Market Value (US$ Million) Forecast by Route of Administration, 2019-2034

Table 39: Middle East and Africa Market Value (US$ Million) Forecast by Indication , 2019-2034

Table 40: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019-2034